Please follow the link below to access A New View of the Spectrum of HER2 Expression and Significance of HER2 Low in Breast Cancer: Exploring the Biology and Updating Best Practices for Testing and Treatment on PeerView's website. This program was developed through the collaboration between the United States and Canadian Academy of Pathology (USCAP) and Peerview.
Authors: Stuart J. Schnitt, MD, Paolo Tarantino, MD, and Jorge S. Reis-Filho, MD, PhD, FRCPath
CME / ABIM MOC 1.5
Released: March 13, 2023
Valid for credit through: April 12, 2024
Activity Description
HER2-low breast cancer, currently defined as HER2 IHC 1+ or 2+/ISH-, accounts for approximately 50% of all breast cancers. While older HER2-targeted therapies did not show efficacy in HER2-low breast cancers, novel antibody–drug conjugates (ADCs) have demonstrated remarkable activity in this setting. Because of these advances and the FDA approval of the first HER2-targeting ADC for HER2-low breast cancer, there is an urgent need to rethink the approaches to HER2 testing so that patients with HER2-low breast cancer could be identified and get a chance to benefit from the new therapeutic approach. The understanding, definitions, and testing for HER2-low status continue to evolve, and many practical challenges and unanswered questions remain.
This PeerView educational activity, based on a recent live symposium, explores the most cutting-edge information on HER2-low breast cancer, provides guidance on how to currently carry out HER2 testing to capture patients with HER2-low expression, and shares what’s on the horizon that may help further refine testing and treatment in this setting.
Target Audience
This activity has been designed to meet the educational needs of pathologists, oncologists, and other healthcare professionals involved in the management of patients with breast cancer.Educational Objectives
Upon completion of this activity, participants should be better able to:- Describe the spectrum of HER2 expression in breast cancer and the role of HER2-low expression as a new therapeutic target
- Implement standard and emerging testing approaches to identify patients with HER2-low metastatic breast cancer to determine their eligibility for novel HER2-targeted therapies
- Apply the latest evidence and guidelines to integrate HER2-targeted therapies into treatment plans for eligible patients with HER2-low metastatic breast cancer in the context of clinical practice or clinical trials
- Collaborate with the multidisciplinary team to ensure appropriate biomarker testing and optimal treatment selection for patients with HER2-low metastatic breast cancer
Disclosures
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.Stuart J. Schnitt, MD
Chief of Breast Oncologic, Pathology Dana-Farber/Brigham and Women’s Cancer Center Associate Director, Dana-Farber/Brigham and Women’s Hospital Breast Oncology Program Professor of Pathology, Harvard Medical School Boston, Massachusetts
Stuart J. Schnitt, MD, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for Ibex; PathAI; and PreciseDX.
Paolo Tarantino, MD
Advanced Research Fellow, Breast Oncology Center Dana-Farber Cancer Institute Harvard Medical School Boston, Massachusetts
Paolo Tarantino, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Daiichi Sankyo, Inc.; and Lilly.
Consultant and/or Advisor for AstraZeneca; Daiichi Sankyo, Inc.; Merck & Co., Inc.; Paige AI, Inc.; Personalis, Inc.; Repare Therapeutics; and Volition Rx.
Jorge S. Reis-Filho, MD, PhD, FRCPath
Pathologist Chief, Experimental Pathology Director, Experimental Pathology Fellowship Department of Pathology Memorial Sloan Kettering Cancer Center New York, New York
Jorge S. Reis-Filho, MD, PhD, FRCPath, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Daiichi Sankyo, Inc.; Merck & Co., Inc.; Paige AI, Inc.; Personalis, Inc.; Repare Therapeutics; and Volition Rx.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Accreditation, Support, and Credit
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Continuing Certification Statement
The activity titled “A New View of the Spectrum of HER2 Expression and Significance of HER2 Low in Breast Cancer: Exploring the Biology and Updating Best Practices for Testing and Treatment” has been registered to offer 1.5 Lifelong Learning credits in the American Board of Pathology’s (ABPath) Continuing Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABPath Continuing Certification credit.
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.